- Conditions
- Heart Failure
- Interventions
- 14 N Sodium Nitrite
- Drug
- Lead sponsor
- Gladwin, Mark, MD
- Individual
- Eligibility
- 70 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1129–1152
of 5,944
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Dravet Syndrome
- Interventions
- EPX-100 (Clemizole Hydrochloride), Placebos
- Drug
- Lead sponsor
- Epygenix
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Fair Lawn, New Jersey
- Conditions
- Tooth Loss, Dental Implant
- Interventions
- Nobel N1 implant
- Device
- Lead sponsor
- Louisiana State University Health Sciences Center in New Orleans
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Hyperphosphatemia
- Interventions
- Calcium Acetate Oral Solution 667 mg per 5 mL, Calcium Acetate 667 mg GelCaps, Calcium Citrate 950 mg Caplets
- Drug · Dietary Supplement
- Lead sponsor
- Fresenius Medical Care North America
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Peri-Implantitis, Dental Implant Failed
- Interventions
- implant decontamination with titanium curette, implant decontamination with Air-Flow device
- Procedure · Device
- Lead sponsor
- Andrea Ravida
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Hematologic Malignancies
- Interventions
- PF-04449913
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 5
- States / cities
- La Jolla, California • San Diego, California • Houston, Texas + 1 more
- Conditions
- ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Hypoxia, Renal Cell Carcinoma, Hypoxia Inducible Factor (HIF), HIF2α Inhibitor, Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha), Hypoxia Inducible Factor 2α (HIF-2α), Clear Cell
- Interventions
- Oral NKT2152
- Drug
- Lead sponsor
- NiKang Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 10 more
- Conditions
- Colorectal Cancer
- Interventions
- 5 FU, Leucovorin, Oxaliplatin, capecitabine [Xeloda]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 627 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 8
- States / cities
- Bakersfield, California • Colorado Springs, Colorado • Washington D.C., District of Columbia + 5 more
- Conditions
- Irritable Bowel Syndrome With Diarrhea (IBS-D)
- Interventions
- MD-7246, Placebo
- Drug
- Lead sponsor
- Ironwood Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 80
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 65 more
- Conditions
- Head and Neck Neoplasms, Mucositis
- Interventions
- Brilacidin, Placebo
- Drug · Other
- Lead sponsor
- Innovation Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 16
- States / cities
- Gilbert, Arizona • Lakeland, Florida • Columbus, Georgia + 13 more
- Conditions
- Healthy Subject, Tobacco Use Disorder
- Interventions
- Laboratory Biomarker Analysis, Phytochemical, Placebo, Screening Questionnaire Administration
- Other · Dietary Supplement
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Hepatitis C, Non-Alcoholic Fatty Liver Disease
- Interventions
- Placebo, Silymarin
- Drug
- Lead sponsor
- National Center for Complementary and Integrative Health (NCCIH)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more
- Conditions
- Atrial Fibrillation, Prescribing Practices, Anticoagulants
- Interventions
- Anticoagulation (AC) Intervention--Academic Detailing, Anticoagulation (AC) Intervention--Prescribing Practices
- Behavioral
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Stroke, Acute, Ischemic Stroke, Hemorrhagic Stroke, Mortality, Morbidity
- Interventions
- Minocycline
- Drug
- Lead sponsor
- Maimonides Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Stage I Squamous Cell Carcinoma of the Oropharynx, Stage II Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Tongue Cancer
- Interventions
- questionnaire administration, quality-of-life assessment
- Other · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Neoplasms, Breast
- Interventions
- Midazolam, Lapatinib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 2
- States / cities
- Lebanon, New Hampshire • Chapel Hill, North Carolina
- Conditions
- Asthma
- Interventions
- Tezepelumab, Placebo
- Biological · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 21
- States / cities
- Bakersfield, California • Newark, Delaware • Kissimmee, Florida + 17 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- nintedanib, placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 347 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 8
- States / cities
- Jasper, Alabama • Danbury, Connecticut • Clearwater, Florida + 5 more
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Interventions
- Paclitaxel, Ricolinostat, Bevacizumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
- Interventions
- vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide
- Biological · Drug
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 14
- States / cities
- Fountain Valley, California • Los Angeles, California • Jacksonville, Florida + 11 more
- Conditions
- Covid19, SARS-CoV Infection
- Interventions
- Shampoo and saline, Saline and Listerine, Shampoo and Listerine, Saline and Saline
- Combination Product
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Hershey, Pennsylvania • State College, Pennsylvania
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Bexagliflozin
- Drug
- Lead sponsor
- Theracos
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Female Patients With Behcet's Syndrome
- Interventions
- Abatacept
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Parkinson Disease
- Interventions
- Placebo, inosine
- Drug
- Lead sponsor
- The Parkinson Study Group
- Network
- Eligibility
- 30 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Manchester, Connecticut • New Haven, Connecticut + 12 more